Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
AML
Decitabine
Midostaurin
Older
Phase II trial
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
05 Oct 2024
05 Oct 2024
Historique:
received:
23
07
2024
accepted:
27
09
2024
medline:
5
10
2024
pubmed:
5
10
2024
entrez:
4
10
2024
Statut:
aheadofprint
Résumé
The treatment of older patients with acute myeloid leukemia (AML) considered unfit for receiving intensive chemotherapy is challenging. Based on the hypothesis that addition of the broad tyrosine kinase inhibitor (TKI) midostaurin could improve the response to hypomethylating agents, irrespective of FLT3 gene mutational status, we conducted a randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to a 10-day schedule of decitabine in unfit (i.e. Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) ≥ 3) AML and higher risk myelodysplasia (MDS) patients (HOVON155 trial). In total, 140 eligible patients were randomly (1:1) assigned to treatment with 10-days of decitabine alone (N = 70) or combined with midostaurin (50 mg bid;starting the day following the last dose of decitabine), (N = 70). Addition of midostaurin was well tolerated and the number of AEs was comparable for both treatment arms. Early death rates (< 30 days) were similar as well (10%). In the decitabine plus midostaurin arm 24% reached CR/CRi, the median OS was 4.8 months and 1-yrs OS was 31% which compared with 34% CR/CRi, median OS of 7.4 months and 1-yrs OS of 37% for the decitabine alone group (NS). Thus, while the addition of midostaurin appears safe, it does not enhance therapeutic efficacy of decitabine in unfit AML patients.
Identifiants
pubmed: 39367118
doi: 10.1007/s00277-024-06033-y
pii: 10.1007/s00277-024-06033-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgard L, Stockelberg D, Didefelt U, Wahlin A, Höglund M (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113:4179–4187
doi: 10.1182/blood-2008-07-172007
Ossenkoppele G, Löwenberg B (2015) How I treat the older patient with acute myeloid leukemia. Blood 125(5):767–774
doi: 10.1182/blood-2014-08-551499
Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562–569
doi: 10.1200/JCO.2009.23.8329
Dombret H, Seymour JF, Butrym A et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts. Blood 126:291–299
doi: 10.1182/blood-2015-01-621664
Kantarjian HM, Thomas XG, Dmoszynska A et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–2677
doi: 10.1200/JCO.2011.38.9429
Blum W, Garzon R, Klisovic RB et al (2010) Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 107:7473–7478
doi: 10.1073/pnas.1002650107
Lübbert M, Wijermans PW, Kicinski M et al (2023) 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. Lancet Haematol 10(11):e879–e889
doi: 10.1016/S2352-3026(23)00273-9
DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617–629
doi: 10.1056/NEJMoa2012971
Montesinos P, Recher C, Vives S et al (2022) Ivosidenib and azacitidine in IDH1-mutated Acute myeloid leukemia. N Engl J Med 386(16):1519–1531
doi: 10.1056/NEJMoa2117344
Williams CB, Kambhampati S, Fiskus W (2013) Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. Pharmacotherapy 33:1341–1352
doi: 10.1002/phar.1316
Karaman MW, Herrgard S, Treiber DK et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127–132
doi: 10.1038/nbt1358
Stone RM, Mandrekar SJ, Sanford BL et al (2017) Midostaurin plus chemotherapy for Acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377(5):454–464
doi: 10.1056/NEJMoa1614359
Schlenk RF, Weber D, Fiedler W et al (2019) Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 133(8):840–851
doi: 10.1182/blood-2018-08-869453
Wang ES, Montesinos P, Minden MD et al (2022) Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut + AML ineligible for intensive chemotherapy. Blood 140(17):1845–1857
doi: 10.1182/blood.2021014586
Giles FJ, Borthakur G, Ravandi F et al (2007) The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136(4):624–627
doi: 10.1111/j.1365-2141.2006.06476.x
Döhner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447
doi: 10.1182/blood-2016-08-733196
Valk PJ, Verhaak RG, Beijen MA et al (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350(16):1617–1628
doi: 10.1056/NEJMoa040465
Jongen-Lavrencic M, Grob T, Hanekamp D et al (2018) Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 378(13):1189–1199
doi: 10.1056/NEJMoa1716863
Terwijn M, van Putten WLJ, Kelder A et al (2013) High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML42A study. J Clin Oncol 31(31):3889–3897
doi: 10.1200/JCO.2012.45.9628
Schuurhuis GJ, Heuser M, Freeman S et al (2018) Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working Party. Blood 131(12):1275–1291
doi: 10.1182/blood-2017-09-801498
Huls G, Chitu DA, Pabst T et al (2020) Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. Blood Adv 4(18):4267–4277
doi: 10.1182/bloodadvances.2020002846
Roboz GJ, Mandrekar SJ, Desai P et al (2018) Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv.:224)
Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL et al (2014) Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol 32:1242–1248
doi: 10.1200/JCO.2013.50.3102
Issa J-P, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E et al (2015) Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 121:556–561
doi: 10.1002/cncr.29085
Ades L, Guerci A, Laribi K, Peterlin P, Vey N, Thepot S et al (2018) A randomized phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS: GFM pick a winner trial. Blood 132:467
doi: 10.1182/blood-2018-99-111756
Craddock CF, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C et al (2017) Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature. Clin Cancer Res 23:6430–6440
doi: 10.1158/1078-0432.CCR-17-1423
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD et al (2017) Randomized Phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745–2753
doi: 10.1200/JCO.2015.66.2510
Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J et al (2017) Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer 123:994–1002
doi: 10.1002/cncr.30533
Cloos JJ, Montesinos P, Fiedler W, Mueller R, Krauter J et al (2021) Midostaurin in patients with newly diagnosed FLT3-mutation negative acute myeloid leukemia: final results and measurable residual disease (MRD) analysis from the Unify tria. Blood 138(S1):1303
doi: 10.1182/blood-2021-148129